Antifibrotic effects of glycyrrhizin and matrine in vitro and in vivo

Biomedicine and Preventive Nutrition

Volumn 2, Issue 2, 2012, Pages 132-137

  Zhao, Jun ^a   Wan, Xu ying ^a   Luo, Ming ^a   Chen, Ting song ^a   He, Ping ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Carbon tetrachloride; Glycyrrhizin; Hepatic fibrosis; HSC T6 cell; Matrine; Rat model

Indexed keywords

COLLAGEN TYPE 1; GLYCYRRHIZIC ACID; LAMININ; MATRINE; PALMITIC ACID; PROCOLLAGEN; PROCOLLAGEN TYPE 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

RATTUS;

EID: 84862825023     PISSN: 22105239     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bionut.2011.12.006     Document Type: Article

References (34)

1. Bissell D.M. Hepatic fibrosis as wound repair: a progress report. J Gastroenterol 1998, 33:295-302.
2. Wasmuth H.E., Weiskirchen R. Pathogenesis of liver fibrosis: modulation of stellate cells by chemokines. Z Gastroenterol 2010, 48:38-45.
3. Friedman S.L. The cellular basis of hepatic fibrosis. N Engl J Med 1993, 328:1828-1835.
4. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
5. Ramachandran P., Iredale J.P. Reversibility of liver fibrosis. Ann Hepatol 2009, 8:283-291.
6. Fowell A.J., Iredale J.P. Emerging therapies for liver fibrosis. Dig Dis 2006, 24:174-183.
7. Yamazaki M. The pharmacological studies on matrine and oxymatrine. Yakugaku Zasshi 2000, 120:25-33. [Review].
8. Long Y., Lin X.T., Zeng K.L., Zhang L. Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2004, 3:69-72.
9. Lin W., Zhang J.P., Hu Z.L., Qian D.H. Inhibitory effect of matrine on lipopolys acchride induced tumor necrosis factor and interleukin-6 production from rat Kupfer cells. Acta Pharm Sin 1997, 32:93-96.
10. Liang P., Bo A.H., Xue G.P. Study on the mechanism of matrine on immune liver injury in rats. World Chin J Digesl (Chinese) 1999, 7:104-108.
11. Zhang J.P., Zhang M., Zhou J.P., Liu F.T., Zhou B., Xie W.F., et al. Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. Acta Pharmacol Sin 2001, 22:183-186.
12. 2+] in guinea pig ventricular myocytes. Acta Pharmacol Sin 2001, 22:512-515.
13. Ma L., Wen S., Zhan Y., He Y., Liu X., Jiang J. Anticancer effects of the Chinese medicine matrine on murine hepatocellular carcinoma cells. Planta Med 2008, 74:245-251.
14. Zhang M.J., Huang J. Recent research progress of antitumor mechanism matrine. Zhongguo Zhong Yao Za Zhi 2004, 29:115-118.
15. Isbrucker R.A., Burdock G.A. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol 2006, 46:167-192.
16. Kurisu S., Inoue I., Kawagoe T., Ishihara M. Clinical profile of patients with symptomatic glycyrrhizin-induced hypokalemia. J Am Geriatr Soc 2008, 56:1579-1581.
17. Asl M.N., Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 2008, 22:709-724.
18. Kimura M., Moro T., Motegi H., Maruyama H., Sekine M., Okamoto H., et al. In vivo glycyrrhizin accelerates liver regeneration and rapidly lowers serum transaminase activities in 70% partially hepatectomized rats. Eur J Pharmacol 2008, 579:357-364.
19. Wan X.Y., Luo M., Li X.D., He P. Hepatoprotective and antihepatocarcinogenic effects of glycyrrhizin and matrine. Chem Biol Interact 2009, 181:15-19.
20. Drachman J.G., Miyakawa Y., Luthi J.N., Dahlen D.D., Raney A., Geddis A.E., et al. Studies with chimeric Mpl/JAK2 receptors indicate that both JAK2 and the membrane-proximal domain of Mpl are required for cellular proliferation. J Biol Chem 2002, 277:23544-23553.
21. Rubin E., Hutterer F., Popper H. Cell proliferation and fiber formation in chronic carbon tetrachloride intoxication. A morphologic and chemical study. Am J Pathol 1963, 42:715-728.
22. Iredale J.P., Benyon R.C., Pickering J., McCullen M., Northrop M., Pawley S., et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998, 102:538-549.
23. Proctor E., Chatamra K. High yield micronodular cirrhosis in the rat. Gastroenterology 1982, 83:1183-1190.
24. Ruwart M.J., Wilkinson K.F., Rush B.D., Vidmar T.J., Peters K.M., Henley K.S., et al. The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat. Hepatology 1989, 10:801-806.
25. Shi H., Dong L., Zhang Y., Bai Y., Zhao J., Zhang L. Protective effect of a coffee preparation (Nescafe pure [R]) against carbon tetrachloride-induced liver fibrosis in rats. Clin Nutr 2010, 29:399-405.
26. Ghosh N., Ghosh R., Mandal V., Mandal S.C. Recent advances in herbal medicine for treatment of liver diseases. Pharm Biol 2011, 49:970-988.
27. Zhang F., Wang X., Tong L., Qiao H., Li X., You L., et al. Matrine attenuates endotoxin-induced acute liver injury after hepatic ischemia/reperfusion in rats. Surg Today 2011, 41:1075-1084.
28. Benyon R.C., Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001, 21:373-384.
29. Hautekeete M.L., Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch 1997, 430:195-207.
30. Lotersztajn S., Julien B., Teixeira-Clerc F., Grenard P., Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005, 45:605-628.
31. Brenner D.A. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 2009, 120:361-368.
32. Gressner A.M. The cell biology of liver fibrogenesis-an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998, 292:447-452.
33. Inao M., Mochida S., Matsui A., Eguchi Y., Yulutuz Y., Wang Y., et al. Japanese herbal medicine Inchin-ko-to as a therapeutic drug for liver fibrosis. J Hepatol 2004, 41:584-591.
34. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247-2250.